Switching from Risperidone to Aripiprazole in early stage of pharmacotherapy will demonstrate the same efficacy as compared to risperidone continuation treatment in the treatment of schizophrenia.
It has been thought that D2 Blocking agent is necessary in acute as well as maintenance phase of pharmacological treatment of patients with schizophrenia. However, this classical strategy produces long term adverse events of drug such as TD, osteoporosis and some metabolic syndrome. To overcome these adverse events, new strategy for pharmacological treatment is needed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
90
Start with risperidone and switch it to aripiprazole. Flexible dose
Start with risperidne and keep it through the end of study. Risperidne:flexible dose
Start with abilify and keep it through the end of study
Dongrae Hospital
Busan, South Korea
RECRUITINGDongseo Hospital
Masan, South Korea
RECRUITINGSANS(Scale for the Assessment of Negative Symptoms)
Time frame: 12 weeks
SARS(Simpson-Angus Rating Scale)
Time frame: 12 weeks
Drug Attitude Inventory
Time frame: 12 weeks
Side effect checklist
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.